KNOW EARLIER. ACT SOONER. STAY HEALTHY.

Preventive health intelligence from blood + AI

We build AI tools that analyze routine biomarkers, multi-omics, and personal health data to surface long-term disease risks and guide prevention. Our first product, IduScore, has been tested with 40 users and will launch in April 2026.

Visit Iduscore Join Early Access

IduScore

IduScore is our first product and is currently in development.

It combines routine blood test values with a short lifestyle questionnaire to deliver clear, easy-to-understand insights into how your wellbeing may evolve over the next 10 years.

It covers four wellbeing areas: cardiovascular (heart), cognitive (brain), respiratory (lungs), and renal (kidneys).

Current stage: MVP tested with 40 users

Planned launch: April 2026 — direct-to-consumer and via an at-home testing company partnership

40

Users tested

April 2026

Target launch

300

Early access members

Visit IduScore Join Early Access

IduScore screenshot showing dashboard overview

IduScore screenshot showing cardiovascular insights

IduScore screenshot showing cognitive score details

IduScore screenshot showing personalized recommendations

About Idunox

Idunox emerged in July 2025 from the work we initiated at TrueYouOmics in January 2024, with a continued focus on multi-omics and AI for early chronic disease detection.

Problem we solve

Each year, chronic diseases claim 43 million lives. ~80% of these deaths are preventable, yet they still occur because the underlying diseases are detected too late.

What we do

We translate routine labs, multi-omics, and personal health data into clear long-term disease risks and preventive action plans.

Target audience

D2C: Health-conscious adults (30-65).
B2B: Blood-testing companies, longevity/preventive clinics, and health insurers.

Industry context

We are based in Switzerland and operate at the intersection of preventive health, biomarker analytics, and digital health decision support.

Team

Dominic Mehr

Co-Founder & CEO

Serial founder with 15+ years of experience across health, consumer, and technology companies, leading strategy, product execution, and partnerships.

Andres Lanzos

Co-Founder & CSO

Biomedical data scientist (PhD) with a decade of experience in multi-omics, biomarkers, biotech, and pharma, leading scientific design and validation.

Guillaume Desachy

Advisor

Head of Biometrics at Pierre Fabre, with prior roles at AstraZeneca and Enterome, advising on biomarker strategy, clinical statistics, and translational data science.